Avacta Group PLC Director's Dealing (1878N)
October 21 2016 - 6:39AM
UK Regulatory
TIDMAVCT
RNS Number : 1878N
Avacta Group PLC
21 October 2016
21 October 2016
Avacta Group plc
("Avacta", "the Group" or "the Company")
Director's Dealing
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics, research and diagnostic reagents, announces that
Dr. Mike Owen, a Non-Executive Director of the Group, has purchased
today 7,763 Ordinary Shares of 10p each in the Group at a price of
90.0 pence per share.
Following this transaction, Dr Owen's total interest in the
Group is 7,763 Ordinary Shares of 10p each, representing less than
0.1% of Avacta's issued share capital.
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
Enquiries:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0)
Geoff Nash / Giles Rolls - Nominated 207 220 0500
Adviser www.finncap.com
Tim Redfern / Alice Lane - Corporate
Broking
Tel: +44 (0)
WG Partners 203 705 9318
David Wilson Tel: +44 (0)
Nigel Barnes 203 705 9217
Claes Spang www.wgpartners.co.uk
Media Enquiries Tel: +44 (0)
FTI Consulting 203 727 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $75bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of targets to enable diagnostics, research assays
and therapeutics.
Avacta has a pre-clinical therapeutic development programme with
an in-house focus on immuno-oncology and bleeding disorders as well
as partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial
responsibilities / person closely associated
------- -------------------------------------------------------------------------------
a) Name Dr Mike Owen
------- ----------------------------------- ------------------------------------------
2. Reason for the Notification
------- -------------------------------------------------------------------------------
a) Position/status Non - Executive Director
------- ----------------------------------- ------------------------------------------
b) Initial notification/Amendment Initial notification
------- ----------------------------------- ------------------------------------------
3. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
------- -------------------------------------------------------------------------------
a) Name Avacta Group Plc
------- ----------------------------------- ------------------------------------------
b) LEI n/a
------- ----------------------------------- ------------------------------------------
4. Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
------- -------------------------------------------------------------------------------
a) Description of Ordinary shares
the Financial of 10p
instrument, type
of instrument
-------
Identification GB00BYYW9G87
code
------- ----------------------------------- ------------------------------------------
b) Nature of the Purchase of 10p Ordinary Shares
transaction
------- ----------------------------------- ------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ---------------- --------------
90.0 pence 7,763
---------------- --------------
------- ----------------------------------- ------------------------------------------
d) Aggregated information:
* Aggregated volume See above
* Price
------- ----------------------------------- ------------------------------------------
e) Date of the transaction 21 October 2016
------- ----------------------------------- ------------------------------------------
f) Place of the London Stock Exchange, AIM
transaction Market (XLON)
------- ----------------------------------- ------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFVIIELLFIR
(END) Dow Jones Newswires
October 21, 2016 06:39 ET (10:39 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024
